Sage Journals: Discover world-class research

Abstract

Multicentre trials are very common in the field of drug development. In recent years, multicentre trials have taken on a multinational and multiregional aspect. We provide a conceptual framework for the use of multicentre trials in the context of drug development, from the perspective of drug regulation in the United States. In this paper, we review some regulatory history, milestones and standards as they relate to multicentre trials. Special attention is given to the similarities and differences in the approaches to multicentre trials in the following documents; Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications, International Conference on Harmonization, Draft Guideline on Statistical Principles for clinical trials and the Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biologic Products. The paper includes a consideration of some of the issues in the analysis of data from multicentre trials.

Get full access to this article

View all access options for this article.

References

US Department of Health and Human Services Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications. Rockville, MD: US Department of Health and Human Services, Public Health Service, Food and Drug Administration , July 1988.

US Department of Health and Human Services Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. US Department of Health and Human Services, Food and Drug Administration , May 1998.

Food and Drug Administration International Conference on Harmonization: Draft Guideline on Statistical Principles for Clinical Trials . Federal Register 1997; 62(90): 25711-25726 .

Freeman P. Discussion of papers . Statistics in Medicine 1998; 17: 1799-1800 .

The University Group Diabetes Program I , ‘Designs, Methods and Baseline Characteristics.’ The Journal of the American Diabetes Association 1970; 19(S2): 747-830 .

‘The Coronary Drug Project.’ The American Heart Association Monograph, No. 38. New York: American Heart Association, 1973.

Federal Food, Drug, and Cosmetic Act, as amended. Washington, DC: US Government Printing Office , 1972: Chapter V, 35-57.

Food and Drug Modernization Act, 1998.

Knatterud G , Rockhold FW , George SL , Davis CE , Fairweather WR , Hanohan T , Mowery R , O’Neill RT. Guidelines for quality assurance in multicentre trials: a position paper . Controlled Clinical Trials 1998; 19: 477-493 .

10.

Longford NT. Selection bias and treatment heterogeneity in clinical trials . Statistics in Medicine 1999; 18: 1467-1474 .

11.

Lu L , Huque M. Understanding on the pooled test for controlled clinical trials . Biometrical Journal 2001; 43(7): 909-923 .

12.

Huster WJ , Louv WC. Demonstration of the reproducibility of treatment efficacy from a single multicentre trial . Journal of Biopharmaceutical Statistics 1992; 2: 2-1-238-2-1-238 .

13.

Fisher LD. One large, well-designed multiple centre study as an alternative to the usual FDA paradigm . Drug Information Journal 1999; 33: 265-327 .

14.

Rosenberger W , Lachin J. Randomization in clinical trials: theory and practice. New York: John Wiley & Sons , 2002.

15.

Fleiss JL. Analysis of data from multi-clinic trials . Controlled Clinical Trials 1986; 7: 267-275 .

16.

Connelly L. Balancing the number and size of sites: an economic approach to the optimal design of cluster samples . Controlled Clinical Trials 2003; 24: 544-559 .

17.

Grizzle JE. Letter to editor . Controlled Clinical Trials 1987; 8: 392-393 .

18.

Permutt T. Probability models and computational models for ANOVA in multicentre clinical trials . Journal of Biopharmaceutical Statistics 2003; 13: 495-505 .

19.

Senn S. Some controversies in planning and analyzing multicentre trials . Statitics in Medicine 1998; 17: 1753-1765 .

20.

Lin Z.

An issue of statistical analysis in controlled multicentre studies: how shall we weight the centres?

Statistics in Medicine 1999; 18: 365-373 .

21.

Gail M , Simon R. Testing for qualitative interactions between treatment effects and patient subsets . Biometrics 1985; 41: 361-372 .

22.

Tsong Y , O’Neill RT. Extreme treatment effects in multicentre trials. Unpublished manuscript.

23.

International Conference on Harmonization E6 . Good clinical practice: consolidated guidance, April 1996.

24.

Food and Drug Administration International Conference on Harmonization: Guidance on ethnic factors in the acceptability of foreign clinical data; Availability . Federal Register 1998; 63(111), 31790-31790 .

25.

Food and Drug Administration Guidance for Industry, Clinical studies section of labeling for prescription drugs and biologic - content and format. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration , May 2001.

26.

International Conference on Harmonization E7 . Guideline for industry: studies in support of special populations: geriatrics, August 1994.

27.

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR=XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group . The Journal of the American Medical Association 2000; 283(10): 1295-1302 .

Multicentre trials: a US regulatory perspective

Abstract

Get full access to this article

References